Wall Street Zen upgraded shares of Nyxoah (NASDAQ:NYXH – Free Report) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.
A number of other brokerages have also weighed in on NYXH. Weiss Ratings reissued a “sell (e+)” rating on shares of Nyxoah in a report on Wednesday, August 19th. Piper Sandler restated an “overweight” rating and issued a $6.00 price objective (down from $7.00) on shares of Nyxoah in a research note on Thursday, August 6th. Oppenheimer set a $4.00 target price on Nyxoah in a report on Thursday, August 6th. Robert W. Baird set a $2.31 target price on Nyxoah in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald cut their price target on shares of Nyxoah to $3.00 and set an “overweight” rating on the stock in a report on Tuesday, October 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.55.
Get Our Latest Stock Report on NYXH
Nyxoah Trading Up 4.3%
NASDAQ:NYXH opened at $0.85 on Friday. Nyxoah has a 12 month low of $0.80 and a 12 month high of $5.92. The firm has a fifty day simple moving average of $1.27 and a 200-day simple moving average of $2.42. The company has a current ratio of 2.38, a quick ratio of 2.31 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $32.78 million, a P/E ratio of -0.43 and a beta of 1.80.
Nyxoah (NASDAQ:NYXH – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. The firm had revenue of $10.39 million for the quarter, compared to the consensus estimate of $11.44 million. Nyxoah had a negative return on equity of 162.01% and a negative net margin of 313.03%. On average, equities research analysts anticipate that Nyxoah will post -1.46 earnings per share for the current year.
Institutional Investors Weigh In On Nyxoah
Several hedge funds have recently added to or reduced their stakes in NYXH. Integrated Wealth Concepts LLC acquired a new stake in Nyxoah during the 2nd quarter worth about $169,000. IFP Advisors Inc raised its stake in shares of Nyxoah by 35.6% during the 2nd quarter. IFP Advisors Inc now owns 118,426 shares of the company’s stock valued at $200,000 after buying an additional 31,061 shares during the last quarter. Readystate Asset Management LP acquired a new position in shares of Nyxoah in the 2nd quarter valued at about $351,000. Finally, AIGH Capital Management LLC lifted its holdings in shares of Nyxoah by 0.7% in the 3rd quarter. AIGH Capital Management LLC now owns 14,632,880 shares of the company’s stock valued at $20,193,000 after buying an additional 98,000 shares during the period.
About Nyxoah
Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.
Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.
Further Reading
- Five stocks we like better than Nyxoah
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
